Minze Health

What Minze Health does

Minze Health NV is a Belgian digital health company founded in 2015 and headquartered in Antwerp, with a secondary US office in Wilmington, Delaware. The company develops a digital urology platform that integrates home-based and in-clinic diagnostics with digital therapeutics, targeting male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH), as well as overactive bladder (OAB). Its commercial product portfolio comprises the Homeflow home-based uroflowmetry device with integrated bladder diary and IPSS scoring for male LUTS/BPH, the Diary Pod automated bladder diary device for OAB diagnostics, the Minze LUTS/BPH Digital Therapy (a 13-week app-based behavioral therapy program), and the Minze Portal clinician-facing platform that aggregates patient data and tracks therapy adherence. A Minze OAB Digital Therapy is in clinical development.

The platform combines proprietary hardware (Homeflow, Diary Pod) with a software ecosystem that captures multi-day voiding behavior data at home and delivers structured behavioral therapy via mobile app. All diagnostic data flows automatically into the Minze Portal, enabling clinicians to review objective reports rather than relying on subjective paper logs or single-visit uroflowmetry snapshots. The company is ISO 13485:2016 certified and a member of AdvaMed.

Minze Health generates revenue through hardware device sales to hospitals and clinics, recurring digital therapeutics subscriptions, and channel partnership revenue. Distribution is hybrid: direct enterprise sales to hospitals and urology practices (deployed across nearly 300 hospitals worldwide), and a three-year EMEA distribution partnership with Medtronic for the Diary Pod tied to Medtronic's Interstim sacral neuromodulation franchise. The company is actively expanding into the US market with prescription digital therapeutics, supported by a $5.3 million funding round raised in October 2024.

Name

Minze Health

Legal name

Minze Health NV

Website

https://minzehealth.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Minze Health NV is a Belgian digital health company that develops a digital urology platform combining home-based uroflowmetry devices, automated bladder diaries, and app-based behavioral therapy for male LUTS/BPH and overactive bladder patients, sold to hospitals, urology clinics, and clinicians across EMEA and the United States.

Ownership category

akta.pro rank

Product category

Urology Medical Devices

NAICS

Health Care and Social Assistance (62)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Urology Telemedicine Platforms (HLALAGAN)

akta.pro secondary industry

Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD)

Keywords

• Digital urology diagnostics
• Home-based uroflowmetry
• Automated bladder diaries
• Digital therapeutics LUTS
• Pelvic health monitoring

Headquarters

HQ city

Antwerp

HQ country

Belgium

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: Sale of hardware devices including Homeflow and Diary Pod to hospitals, clinics, and healthcare providers for diagnostic purposes.
2. Digital Therapeutics Subscription: Prescription digital therapeutics delivered via app-based platform, likely sold as subscription to healthcare providers or health systems.
3. Distribution Partnership Revenue: Revenue generated through Medtronic partnership for distribution of Diary Pod across EMEA markets.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Minze Health builds a digital urology platform combining proprietary medical devices (Homeflow home-based uroflowmetry and Diary Pod automated bladder diary) with app-based digital behavioral therapy programs for male Lower Urinary Tract Symptoms (LUTS), Benign Prostatic Hyperplasia (BPH), and Overactive Bladder (OAB). Diagnostic data flows automatically from devices into the Minze Portal, a clinician-facing platform used by hospitals and urology clinics for patient monitoring and treatment.

Product overview

Minze Health offers a unified digital health platform integrating digital diagnostics and therapeutics for male LUTS/BPH and OAB. The product portfolio consists of three core commercial products: Homeflow (home-based uroflowmetry device for LUTS/BPH diagnostics), Diary Pod (automated bladder diary for OAB diagnostics), and Minze LUTS/BPH Digital Therapy (13-week app-based behavioral therapy). An OAB Digital Therapy is currently in clinical development. All diagnostic devices connect to the Minze Portal, a clinician-facing platform that automatically receives device reports and enables patient monitoring. The products work together to provide a complete pathway from symptom assessment to treatment, combining in-clinic and home-based diagnostics with scalable digital therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• Homeflow Home-based uroflowmetry device for non-invasive Male LUTS/BPH diagnostics. Combines uroflowmetry, bladder diary, and IPSS scoring in a single home device; patient measures from home over multiple days and reports flow automatically into the Minze Portal for clinician review.
• Diary Pod Automated bladder diary device for OAB (Overactive Bladder) diagnostics. Captures voided volume and time automatically and pairs with the Flow app for patients to tag urgency and intake, producing a 2-3 day automated diary that flows into the Minze Portal.
• Minze LUTS/BPH Digital Therapy 13-week evidence-based app-based digital behavioral therapy program for Male LUTS and BPH. Includes weekly modules, daily tips, bladder training, lifestyle guidance, objective symptom tracking, and a clinician dashboard for monitoring progress and adherence.
• Minze Portal Clinician-facing web portal that automatically ingests reports from Homeflow and Diary Pod devices and presents ready-to-review patient data, enabling clinicians to monitor diagnostic results, therapy adherence, and patient progress.

Quantifiable outcome

• 80 million adults affected by LUTS in the U.S.; over 90 million in the EU
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Medtronic plccoreChannel Partner/ Reseller/ Distributor · 12 November 2025Minze Health NV signed a three-year partnership agreement with Medtronic to distribute Minze's app-controlled urine collection device (Diary Pod) across EMEA markets. The Diary Pod is designed to support patients with overactive bladder receiving sacral neuromodulation therapy with Medtronic's Interstim system. The deal enhances Medtronic's urology portfolio while expanding Minze's commercial reach through an established medtech distribution partner.

Scale indicators4 records

Recent moves6 records

Expansion highlights8 records

Direct peers

• iUFlow: iUFlow offers a home-based uroflowmetry device with companion app for bladder monitoring, making it the closest direct competitor to Minze's Homeflow in remote urology diagnostics.
• Pelvital: Pelvital develops FDA-cleared medical devices and digital tools for pelvic floor disorders including urinary incontinence, overlapping with Minze's OAB and pelvic health focus area.
• MediTuner: MediTuner builds app-based digital therapeutics for urinary incontinence and related conditions, directly overlapping Minze's OAB and LUTS/BPH behavioral therapy offerings.

Emerging players

• Bold Health (Mahana Therapeutics): Bold Health/Mahana develops prescription digital therapeutics for chronic GI and related conditions, sharing Minze's DTx business model and regulatory pathway into prescription digital therapy.
• Kaia Health: Kaia Health is a European-headquartered digital therapeutics company offering app-based behavioral therapy programs for MSK pain and COPD, comparable as a peer European DTx scale-up.
• Sword Health: Sword Health is a digital musculoskeletal therapy leader with a similar prescription DTx go-to-market model, comparable as a peer in the digital therapeutics commercialization playbook.
• Augury: Augury combines proprietary hardware sensors with AI-driven software analytics in industrial/health monitoring, sharing Minze's hardware-plus-software-platform commercialization approach.

Broad incumbents

• Laborie Medical Technologies: Laborie is a global urology and pelvic health medical device incumbent with established uroflowmetry and urodynamics products, competing with Minze's diagnostic devices in hospital channels.
• Coloplast: Coloplast is a global leader in urology and continence care products, with installed relationships across urology practices that Minze must penetrate to scale its OAB and BPH solutions.
• Boston Scientific: Boston Scientific has a large urology portfolio (including prostate and OAB therapies) and the R&D and clinical-trial capacity to enter adjacent digital diagnostics, representing a significant competitive threat.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/minzehealth
• YouTubeyoutube.com/channel/UCquoY9PcOxHmOdO_P8rkjsw/featured
• Facebookfacebook.com/minzehealth
• LinkedInlinkedin.com/company/minze-health

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Minze Health